Can 18F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer?

Clinical Nuclear Medicine

Volumn 38, Issue 4, 2013, Pages 263-265

  Ul Hassan, Fahim ^a   Simo, Ricard ^b   Guerrero Urbano, Teresa ^b   Oakley, Richard ^b   Jeannon, Jean Pierre ^b   Cook, Gary ^c  

^a Nuclear Medicine Department   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

18F FDG PET CT; chemoradiotherapy; head and neck cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; MALE; MONOTHERAPY; NASOPHARYNX CANCER; OROPHARYNX CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HEAD AND NECK TUMOR; LABORATORY DIAGNOSIS; MIDDLE AGED; RADIOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875231019     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31828165a8     Document Type: Article

References (11)

1. Annertz K, Anderson H, Biörklund A, et al. Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. Int J Cancer. 2002;101:95-99.
2. Schantz SP, Yu GP. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg. 2002;128:268-274.
3. Llewellyn CD, Johnson NW, Warnakulasuriya KA. Risk factors for squamous cell carcinoma of the oral cavity in young peopleYa comprehensive literature review. Oral Oncol. 2001;37:401-418.
4. Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. MACH-NC Collaborative Group. Radiother Oncol. 2009; 92:4-14.
5. Eisbruch A, Marsh LH, Dawson LA, et al. Recurrences near base of skull after IMRT for head-and-neck cancer: Implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys. 2004; 59:28-42.
6. Lee N, Xia P, Fischbein NJ. Intensity-modulated radiation therapy for headand-neck cancer: The UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003;57:49-60.
7. Hermans R. Posttreatment imaging in head and neck cancer. Eur J Radiol. 2008;66:501-511.
8. Lell M, Baum U, Greess H, et al. Head and neck tumors: Imaging recurrent tumor and post-therapeutic changes with CT and MRI. Eur J Radiol. 2000; 33:239-247.
9. Brizel DM, Lydiatt W, Colevas AD. Controversies in the locoregional management of head and neck cancer. J Natl Compr Canc Netw. 2011;9:653-662.
10. Gupta T, Master Z, Kannan S, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083-2095.
11. Pang L, Jeannon JP, Simo R. Minimizing complications in salvage head and neck oncological surgery following radiotherapy and chemo-radiotherapy. Curr Opin Otolaryngol Head Neck Surg. 2011;19:125-131.